What is the share price of Global Health Ltd (MEDANTA) today?
The share price of MEDANTA as on 17th July 2025 is ₹1345.10. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Global Health Ltd (MEDANTA) share?
The past returns of Global Health Ltd (MEDANTA) share are- Past 1 week: 5.69%
- Past 1 month: 9.28%
- Past 3 months: 5.99%
- Past 6 months: 31.78%
- Past 1 year: 11.71%
- Past 3 years: N/A%
- Past 5 years: 223.89%
What are the peers or stocks similar to Global Health Ltd (MEDANTA)?
The peers or stocks similar to Global Health Ltd (MEDANTA) include:What is the dividend yield % of Global Health Ltd (MEDANTA) share?
The current dividend yield of Global Health Ltd (MEDANTA) is 0.04.What is the market cap of Global Health Ltd (MEDANTA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Global Health Ltd (MEDANTA) is ₹36152.30 Cr as of 17th July 2025.What is the 52 week high and low of Global Health Ltd (MEDANTA) share?
The 52-week high of Global Health Ltd (MEDANTA) is ₹1349 and the 52-week low is ₹935.50.What is the PE and PB ratio of Global Health Ltd (MEDANTA) stock?
The P/E (price-to-earnings) ratio of Global Health Ltd (MEDANTA) is 75.09. The P/B (price-to-book) ratio is 12.69.Which sector does Global Health Ltd (MEDANTA) belong to?
Global Health Ltd (MEDANTA) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.How to buy Global Health Ltd (MEDANTA) shares?
You can directly buy Global Health Ltd (MEDANTA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Global Health Ltd
MEDANTA Share Price
MEDANTA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is overpriced and in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
MEDANTA Performance & Key Metrics
MEDANTA Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
75.10 | 12.69 | 0.04% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
37.54 | 6.51 | 0.80% |
from 14 analysts
Price Upside
Earnings Growth
Rev. Growth
MEDANTA Company Profile
Global Health Limited, formerly Global Health Private Limited, is an India-based company. The Company is a tertiary care provider operating in the North and East regions of India. The Company operates approximately four hospitals under Medanta brand
MEDANTA Sentiment Analysis
MEDANTA Sentiment Analysis
MEDANTA Stock Summary · May 2025
In the fourth quarter, the company demonstrated robust financial performance, achieving a consolidated income of INR 37,714 million, driven by a 13% year-on-year growth and a strong EBITDA margin of 25.4%. Strategic initiatives, including the successful merger with the Lucknow unit and a substantial capital expenditure plan of INR 4,000 crores, are set to enhance operational efficiency and expand bed capacity, addressing the growing healthcare demands in key regions. Despite challenges such as fluctuating average revenue per occupied bed and increased competition, the company remains optimistic about future growth, particularly in underserved markets like Noida and Patna. Enhanced investor engagement and transparency efforts further bolster market sentiment, reflecting confidence in the company’s long-term trajectory.
MEDANTA Stock Growth Drivers
MEDANTA Stock Growth Drivers
7Clinical Excellence and Innovations
The company has achieved significant milestones in advanced cancer care, including the successful implementation of
Financial Performance and Growth
The company reported a total consolidated income of INR 37,714 million for FY25, reflecting a
MEDANTA Stock Challenges
MEDANTA Stock Challenges
4Challenges in Pre-Engineered Building Adoption
The company faces significant challenges in adopting pre-engineered buildings in the hospital sector due to
Negative Impact of Seasonal Festivals on Operations
The company has observed a negative impact on elective surgeries during seasonal festivals, including the
MEDANTA Forecast
MEDANTA Forecasts
Price
Revenue
Earnings
MEDANTA Share Price Forecast
MEDANTA Share Price Forecast
All values in ₹
All values in ₹
MEDANTA Company Revenue Forecast
MEDANTA Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
MEDANTA Stock EPS (Earnings Per Share) Forecast
MEDANTA Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
MEDANTA
MEDANTA
Income
Balance Sheet
Cash Flow
MEDANTA Income Statement
MEDANTA Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 1,344.00 | 1,392.14 | 1,505.82 | 1,515.63 | 1,255.75 | 1,800.00 | 2,021.13 | 2,382.88 | 3,771.41 | 3,771.41 | ||||||||||
Raw Materials | 287.89 | 313.43 | 324.92 | 319.21 | 301.73 | 451.23 | 459.11 | 540.96 | 2,865.15 | 2,865.16 | ||||||||||
Power & Fuel Cost | 30.63 | 29.55 | 30.65 | 31.11 | 27.43 | 31.80 | 36.84 | 35.86 | ||||||||||||
Employee Cost | 518.07 | 526.60 | 540.72 | 522.30 | 415.91 | 494.66 | 532.91 | 591.06 | ||||||||||||
Selling & Administrative Expenses | 170.86 | 211.56 | 244.28 | 116.95 | 271.25 | 327.42 | 411.71 | 488.02 | ||||||||||||
Operating & Other expenses | 151.10 | 137.01 | 156.91 | 264.02 | 38.16 | 79.06 | 110.94 | 120.75 | ||||||||||||
EBITDA | 185.45 | 173.99 | 208.34 | 262.04 | 201.27 | 415.83 | 469.62 | 606.23 | 906.26 | 906.25 | ||||||||||
Depreciation/Amortization | 77.35 | 86.36 | 90.69 | 98.57 | 87.64 | 87.17 | 86.09 | 87.09 | 193.75 | 193.75 | ||||||||||
PBIT | 108.10 | 87.63 | 117.65 | 163.47 | 113.63 | 328.66 | 383.53 | 519.14 | 712.51 | 712.50 | ||||||||||
Interest & Other Items | 19.05 | 23.56 | 21.13 | 32.54 | 29.20 | 32.83 | 31.82 | 30.46 | 65.26 | 65.27 | ||||||||||
PBT | 89.05 | 64.07 | 96.52 | 130.93 | 84.43 | 295.83 | 351.71 | 488.68 | 647.25 | 647.23 | ||||||||||
Taxes & Other Items | 34.70 | 26.74 | 33.58 | 28.18 | 27.14 | 77.04 | 88.46 | 127.78 | 165.82 | 165.82 | ||||||||||
Net Income | 54.35 | 37.33 | 62.94 | 102.75 | 57.29 | 218.79 | 263.25 | 360.90 | 481.43 | 481.41 | ||||||||||
EPS | 2.24 | 1.53 | 2.57 | 4.17 | 2.32 | 8.73 | 10.10 | 13.45 | 17.92 | 17.93 | ||||||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.50 | 0.00 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 |
MEDANTA Company Updates
MEDANTA Stock Peers
MEDANTA Past Performance & Peer Comparison
MEDANTA Past Performance & Peer Comparison
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Global Health Ltd | 75.09 | 12.69 | 0.04% |
Max Healthcare Institute Ltd | 112.37 | 12.89 | 0.12% |
Apollo Hospitals Enterprise Ltd | 73.10 | 14.44 | 0.38% |
Fortis Healthcare Ltd | 79.01 | 6.67 | 0.12% |
MEDANTA Stock Price Comparison
Compare MEDANTA with any stock or ETFMEDANTA Holdings
MEDANTA Shareholdings
MEDANTA Promoter Holdings Trend
MEDANTA Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
MEDANTA Institutional Holdings Trend
MEDANTA Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
MEDANTA Shareholding Pattern
MEDANTA Shareholding Pattern
MEDANTA Shareholding History
MEDANTA Shareholding History
Mutual Funds Invested in MEDANTA
Mutual Funds Invested in MEDANTA
No mutual funds holding trends are available
Top 5 Mutual Funds holding Global Health Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.3719% | Percentage of the fund’s portfolio invested in the stock 1.49% | Change in the portfolio weight of the stock over the last 3 months -0.37% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 50/70 (-3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8269% | Percentage of the fund’s portfolio invested in the stock 1.13% | Change in the portfolio weight of the stock over the last 3 months -0.15% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 47/64 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6904% | Percentage of the fund’s portfolio invested in the stock 0.95% | Change in the portfolio weight of the stock over the last 3 months -0.12% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 60/117 (-33) |
Compare 3-month MF holding change on Screener
smallcases containing MEDANTA stock
smallcases containing MEDANTA stock
Looks like this stock is not in any smallcase yet.
MEDANTA Events
MEDANTA Events
MEDANTA Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
MEDANTA Dividend Trend
No dividend trend available
MEDANTA Dividends
MEDANTA Dividends
MEDANTA Stock News & Opinions
MEDANTA Stock News & Opinions
PCBL Chemical Ltd, Elgi Equipments Ltd, Syrma SGS Technology Ltd, Sammaan Capital Ltd are among the other stocks to see a surge in volumes on NSE today, 09 July 2025.Global Health Ltd saw volume of 48.81 lakh shares by 14:14 IST on NSE, a 19.84 fold spurt over two-week average daily volume of 2.46 lakh shares. The stock increased 5.20% to Rs.1,281.40. Volumes stood at 2.93 lakh shares in the last session.PCBL Chemical Ltd notched up volume of 94.32 lakh shares by 14:14 IST on NSE, a 10.31 fold spurt over two-week average daily volume of 9.15 lakh shares. The stock rose 5.43% to Rs.426.30. Volumes stood at 6.51 lakh shares in the last session.Elgi Equipments Ltd recorded volume of 58.32 lakh shares by 14:14 IST on NSE, a 9.2 times surge over two-week average daily volume of 6.34 lakh shares. The stock gained 4.01% to Rs.555.50. Volumes stood at 32.93 lakh shares in the last session.Syrma SGS Technology Ltd notched up volume of 112.43 lakh shares by 14:14 IST on NSE, a 6.76 fold spurt over two-week average daily volume of 16.64 lakh shares. The stock rose 4.32% to Rs.641.75. Volumes stood at 5.31 lakh shares in the last session.Sammaan Capital Ltd saw volume of 627.72 lakh shares by 14:14 IST on NSE, a 5.35 fold spurt over two-week average daily volume of 117.29 lakh shares. The stock increased 2.13% to Rs.127.75. Volumes stood at 124.1 lakh shares in the last session.Powered by Capital Market - Live
Global Health has allotted 20,000 equity shares under ESOP and 90,000 equity shares under to GHL Employees Welfare Trust ('ESOP Trust') under Part -B of GHL LTIP 2024 Plan i.e. GHL Employees Stock Purchase Scheme, 2024. Post aforesaid allotments, the paid-up share capital of the Company has increased from Rs 53,73,20,764/- divided into 26,86,60,382 equity shares of Rs. 2 each to Rs. 53,75,40,764/- divided into 26,87,70,382 equity shares of Rs. 2/- each.Powered by Capital Market - Live
Net profit of Global Health declined 20.40% to Rs 101.40 crore in the quarter ended March 2025 as against Rs 127.38 crore during the previous quarter ended March 2024. Sales rose 15.16% to Rs 931.25 crore in the quarter ended March 2025 as against Rs 808.63 crore during the previous quarter ended March 2024. For the full year,net profit rose 0.68% to Rs 481.44 crore in the year ended March 2025 as against Rs 478.19 crore during the previous year ended March 2024. Sales rose 12.74% to Rs 3692.32 crore in the year ended March 2025 as against Rs 3275.11 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales931.25808.63 15 3692.323275.11 13 OPM %24.1322.18 -23.7524.40 - PBDT232.59188.54 23 890.91799.83 11 PBT183.34143.09 28 697.16627.10 11 NP101.40127.38 -20 481.44478.19 1 Powered by Capital Market - Live
Global Health announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 25%) , subject to the approval of the shareholders.Powered by Capital Market - Live
Global Health has allotted 73,000 equity shares to GHL Employee Welfare Trust ('ESOP Trust') under Part -B of GHL LTIP 2024 Plan i.e. GHL Employees Stock Purchase Scheme, 2024. Post allotment, the paid up equity share capital has increased to Rs. 53,73,20,764/- divided into 26,86,60,382 equity shares of Rs. 2/- each.Powered by Capital Market - Live
Global Health will hold a meeting of the Board of Directors of the Company on 15 May 2025.Powered by Capital Market - Live
Global Health 'Medanta' announced its entry into the North East with its plan to establish a super speciality hospital in Guwahati. The Board of Directors, in its meeting held today, approved the purchase of 3 acres of land from Assam Electricity Grid Corporation for Rs. 30 crore plus incidental expenses for registration and possession of the land. The Board has also approved plans to invest approximately Rs. 500 crore including cost of land in developing a state-of-the-art, 400-bed super specialty hospital. Proposed site is strategically located on National Highway 27, offering seamless connectivity across the entire North East region. This expansion aims to strengthen healthcare infrastructure and will serve over 50 million people across Assam and its neighbouring states. Medanta's foray into the region will be transformative, bringing world-class medical expertise, cutting-edge technology and comprehensive care across more than 20 super specialties, including transplants and advanced robotic procedures. Powered by Capital Market - Live
Global Health has approved the grant of 5,85,500 Options and Offer of 2,03,000 Shares to certain eligible employees under Part -A and Part- B of GHL Long Term Share Based Incentive Plan - 2024 (GHL LTIP 2024 Plan), respectively.Powered by Capital Market - Live
The company intends to develop a super speciality hospital on this land. Global Health operates hospitals in Gurugram, Indore, Ranchi, Lucknow and Patna. The company's consolidated operational bed count stood at nearly 2,373 beds as on 31 March 2024. The scrip fell 1.71% to currently trade at Rs 1212 on the BSE. Powered by Capital Market - Live
Crisil Ratings stated that GHL's Revenue reported 12% on-year growth in the first nine months of fiscal 2025, driven by increase in inpatient volumes owing to bed expansion, improvement in average revenue per occupied bed (ARPOB) and sustenance of occupancy levels on year on-year basis. Operating profitability moderated by 50 basis points (bps) to 24.1% in the first nine months of fiscal 2025 due to decline in operating profitability in the Lucknow hospital while the Patna (Bihar) and Gurugram (Haryana) hospitals registered stable profitability. At a consolidated level, GHL's revenue may grow 10-12% in fiscal 2025, supported by bed additions, sustenance of occupancy levels at overall level and improvement in ARPOB due to change in case mix. Operating profitability is expected to sustain at 22-24% despite the moderation expected in the Lucknow hospital due to better profitability in other hospitals, although pre-operative expenses towards bed additions at existing hospitals and commencement of the hospital at Noida (Uttar Pradesh) expected towards the end of fiscal 2025 might partly constrain profitability. On consolidated basis, revenue grew 21% to Rs 3,278 crore in fiscal 2024 (from Rs 2,712 crore in fiscal 2023), driven by higher inpatient volumes, changes in specialty mix towards higher value specialties leading to better ARPOB as well as better scale up of the Lucknow and Patna hospitals. The financial risk profile is supported by strong capital structure, healthy debt protection metrics and liquidity. Consolidated adjusted networth stood at Rs 2,900 crore and debt (including lease liabilities) at Rs 802 crore as on 31 March 2024, with gearing at 0.28 time. GHL has planned capital expenditure (capex) of more than Rs ~2,500 crore over the next 3-5 fiscals. The capex will be funded through a prudent mix of cash accrual and debt. Even though the company may avail of external debt, gearing is expected below 0.5 time over the medium term. The ratings continue to reflect the experienced management of GHL in therapeutic segments and healthy financial risk profile. These strengths are partially offset by risks related to implementation and timely stabilisation of upcoming hospitals, geographic and therapeutic segmental concentration in revenue and exposure to intense competition. Global Health operates hospitals in Gurugram, Indore, Ranchi, Lucknow and Patna. The company's consolidated operational bed count stood at nearly 2,373 beds as on 31 March 2024. The scrip shed 0.64% to currently trade at Rs 1227.95 on the BSE. Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 20%, vs industry avg of 12.95%
Over the last 5 years, market share increased from 3.56% to 4.74%
Over the last 5 years, net income has grown at a yearly rate of 36.19%, vs industry avg of 41.11%